C
Calluna Pharma
Biotech & Life Sciences · Oslo, Norway · Founded 2024
Creating pioneering treatments to combat chronic inflammation and fibrosis from their root causes MoreLess
Calluna Pharma is a clinical-stage biotechnology company that specializes in the development of therapies for inflammatory and fibrotic diseases. The company is focused on creating selective antibodies that target immunological diseases with enhanced efficacy. Their pipeline includes several first-in-class clinical candidates, with their lead product being CAL101, which has completed a Phase 1 clinical study for fibrotic and fibro-inflammatory indications. Calluna Pharma operates in the biotechnology market, a sector characterized by high research and development costs and long product development timelines. The company's business model is centered on the discovery and clinical development of novel drug candidates. Their revenue generation will likely depend on partnerships with larger pharmaceutical companies for further development, manufacturing, and commercialization, or through the eventual sale of their developed therapies. The company has recently secured significant funding through a €75 million Series A financing round, which will support the advancement of its product pipeline.
Keywords: biotechnology, immunology, fibrotic diseases, antibody therapies, clinical-stage, CAL101, Series A financing, drug development, inflammatory diseases, clinical trials
Company overview
Calluna Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2024
- Headquarters
- Oslo, Norway
- Employees
- 27
- Open positions
- 1
- Dealroom signal
- 86.4
Valuation & funding
Calluna Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2024 | $83M | $330M | Investinor · Sarsia · Forbion Capital Partners · p53 Invest | ↗ |
Growth signals
Calluna Pharma website traffic
Latest recorded traffic for Calluna Pharma is 1.9K monthly website visits, up 46.2% over the last three months. Calluna Pharma's team grew 12.5% over the past year.
Hiring
Open positions at Calluna Pharma
Current openings linked to this company in Dealroom.
Comparisons
Calluna Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Calluna Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Calluna Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Calluna Pharma has talent and traffic
team presence
In the news
Latest news about Calluna Pharma
Recent press, funding announcements, and product moves mentioning Calluna Pharma — open to read from the original sources.
Market sentiment
What the market is saying about Calluna Pharma
An AI-synthesized read of the highest-engagement posts about Calluna Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Calluna Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.